2810 related articles for article (PubMed ID: 19005398)
41. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results.
Krämer BK; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Ortuño J; Sester U; Kunzendorf U; Dietl KH; Bonomini V; Rigotti P; Ronco C; Tabernero JM; Rivero M; Banas B; Mühlbacher F; Arias M; Montagnino G;
Nephrol Dial Transplant; 2008 Jul; 23(7):2386-92. PubMed ID: 18258740
[TBL] [Abstract][Full Text] [Related]
43. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
44. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial.
Franz S; Regeniter A; Hopfer H; Mihatsch M; Dickenmann M
Am J Kidney Dis; 2010 Feb; 55(2):335-43. PubMed ID: 19926370
[TBL] [Abstract][Full Text] [Related]
45. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B
Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2384-5. PubMed ID: 15561256
[TBL] [Abstract][Full Text] [Related]
47. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
48. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
[TBL] [Abstract][Full Text] [Related]
49. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
50. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
[TBL] [Abstract][Full Text] [Related]
51. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
Stallone G; Di Paolo S; Schena A; Infante B; Grandaliano G; Battaglia M; Gesualdo L; Schena FP
Transplantation; 2003 Apr; 75(7):998-1003. PubMed ID: 12698087
[TBL] [Abstract][Full Text] [Related]
52. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
[TBL] [Abstract][Full Text] [Related]
53. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
[TBL] [Abstract][Full Text] [Related]
54. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
Opelz G; Döhler B;
Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
[TBL] [Abstract][Full Text] [Related]
55. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
[TBL] [Abstract][Full Text] [Related]
56. Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies.
Töz H; Sen S; Seziş M; Duman S; Ozkahya M; Ozbek S; Hoşcoşkun C; Atabay G; Ok E
Transplant Proc; 2004; 36(1):134-6. PubMed ID: 15013324
[TBL] [Abstract][Full Text] [Related]
57. Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients.
Niemczyk M; Nowak M; Pilecki T; Wyzgał J; Ziółkowski J; Zygier D; Paczek L
Transplant Proc; 2006; 38(1):74-7. PubMed ID: 16504668
[TBL] [Abstract][Full Text] [Related]
58. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial.
Oberbauer R; Hutchison B; Eris J; Arias M; Claesson K; Mota A; Kreis H; Kleinman L; Wang F; Chen J; Revicki DA;
Transplantation; 2003 Apr; 75(8):1277-85. PubMed ID: 12717216
[TBL] [Abstract][Full Text] [Related]
59. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection.
Mathew TH; Van Buren C; Kahan BD; Butt K; Hariharan S; Zimmerman JJ
J Clin Pharmacol; 2006 Jan; 46(1):76-87. PubMed ID: 16397287
[TBL] [Abstract][Full Text] [Related]
60. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
Hsu HJ; Tian YC; Chen YC; Lai BC; Fang JT; Yang CW; Wu MS
Ren Fail; 2008; 30(3):303-6. PubMed ID: 18350450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
